InMed Pharmaceuticals

InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons. During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the...

On Thursday at 11 a.m. EST, Benzinga will host a Healthcare & Biotech Breakthroughs virtual conference. This online event will bring together industry leaders to discuss recent advancements in healthcare and biotechnology that are transforming patient care and creating new investment avenues....

Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all. The leader in cannabinoids and cannabinoid analogs pharmaceutical research, development, manufacturing and...

When it comes to treating degenerative diseases like Alzheimer’s, much of the current focus is on addressing the symptoms rather than repairing and regenerating the damaged tissues and cells. Some drugs and treatments may slow the progression of cognitive decline, but none can reverse the...

InMed Pharmaceuticals (NASDAQ: INM) is a global leader in researching, developing, manufacturing and commercializing rare cannabinoids and cannabinoid analogs. The company is focused on the therapeutic benefits of cannabinol (CBN) as a pipeline of cannabinoid-based drug candidates for the treatment...

BayMedica, a rare cannabinoids supplier for the health and wellness sector acquired by InMed Pharmaceuticals (NASDAQ: INM) in 2021, is scaling up its manufacturing process to meet growing demand. That includes optimizing its supply chain, increasing production, and continuing its research on rare...

InMed Pharmaceuticals Inc. (NASDAQ: INM), a biopharmaceutical company that is dedicated to advancing research and therapies for a wide range of medical conditions, has reported that it has made some significant strides in the development of treatments for epidermolysis bullosa, glaucoma, and...

Neurodegenerative diseases such as Parkinson’s, Alzheimer's and others are increasing worldwide as the population ages. According to Alzheimer's Disease International, more than 50 million persons lived with dementia worldwide in 2020, and roughly 1.2 million people in the United...

Shane Johnson, SVP and General Manager of Baymedica of InMed Pharmaceuticals (NASDAQ: INM), was a guest speaker at Benzinga’s All Access on June 17th, 2022.  InMed Pharmaceuticals is an emerging global leader in the development, manufacturing and commercialization of rare cannabinoids...

InMed Pharmaceuticals (NASDAQ: INM) announced on Monday that it has entered into a definitive agreement to acquire BayMedica Inc., a private company that manufactures rare cannabinoids. Once the agreement is completed, InMed could become a global leader in the manufacturing...